Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue... Show more
Profound Medical is a commercial-stage medical device company focused on interventional MRI (magnetic resonance imaging) procedures, with its flagship TULSA-PRO platform enabling MRI-guided, incision-free prostate ablation. As a pre-profitability company, its quarterly results are closely watched less for earnings than for evidence of commercial traction: revenue growth, installed-base expansion, procedure utilization, and the pace of cash consumption. The third quarter of 2026 marks an important inflection point as management works to convert a growing pipeline and broader payer coverage into system placements and recurring procedure revenue, while a leadership transition looms on the horizon.
For the three months ended September 30, 2026, Profound Medical reported total revenue of $9.8 million, up 86% from $5.29 million in the third quarter of 2025 and slightly above the roughly $9.8 million consensus estimate. Revenue comprised $5.7 million from capital equipment sales and $4.1 million in recurring non-capital revenue from single-use devices and extended-warranty services.
Gross margin improved to 78% from 74% a year earlier, while operating expenses increased 21% to $15.5 million, driven by higher headcount, commissions, travel, and consulting costs, partly offset by lower clinical-trial spending after completion of CAPTAIN trial enrollment.
The net loss narrowed 3% to approximately $7.7 million, or $0.21 per common share, compared with approximately $8.0 million, or $0.26 per share, in the prior-year quarter. The per-share loss was slightly wider than the $0.19 consensus expectation. Cash used in operating activities fell to $5.0 million from $11.3 million in the second quarter of 2026.
The company ended the quarter with 98 TULSA-PRO systems installed, a qualified sales pipeline of about $79.2 million, and approximately $33.3 million in cash. Management raised its 2026 revenue outlook to "at least $25 million" and reiterated a full-year gross margin of 70% or higher.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following companies like Profound Medical, it offers a structured way to surface potential setups across the broader market.
Investor reaction to Profound Medical's third-quarter results was shaped by a tension between strong top-line momentum and a bottom line that still fell short of expectations. The record revenue and improved gross margin underscored accelerating adoption of TULSA-PRO, but the slightly wider-than-expected per-share loss and a roughly $3.1 million portion of revenue that management said reflected shipments slipping from the prior quarter prompted closer scrutiny of the underlying growth trajectory. Sentiment also centered on the retirement of the company's "Index 20" utilization metric, which reduced transparency around procedure-volume trends just as utilization becomes a key proof point, and on the outlook for the Cook Medical and Telix partnerships.
Looking ahead, investors will be watching several catalysts tied to Profound Medical's push toward sustainable, profitable growth.
The newly signed supply and distribution agreement with Cook Medical, which adds TULSA-PRO to Cook's Copernicus iMRI (interventional MRI) offering, is a central focus. Management has indicated the material revenue contribution from this channel is not expected until the second half of 2027, making near-term execution still dependent on the company's direct sales team. A co-education partnership with Telix is expected to expand physician outreach, though its commercial impact will take time to develop.
Reimbursement remains another key factor. Management highlighted the CMS (Centers for Medicare & Medicaid Services) 2027 final rule, which set ambulatory surgery center (ASC) reimbursement for the TULSA procedure at roughly $11,400 — a level management views as competitive with robotic surgery in hospital settings. Progress on payer coverage, including the addition of about 10.7 million covered lives during the quarter, will also be important to watch.
Finally, a leadership transition adds a layer of execution risk to monitor. Richard Fabian is set to become CEO on January 14, 2027, with current CEO Arun Menawat moving to executive chairman. Investors will likely focus on how the new leadership converts the company's expanding pipeline and installed base into accelerating recurring revenue while preserving the improving gross-margin profile and moderating cash burn.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer and manufacturee of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology
Industry MedicalNursingServices